Early switch strategy in patients with major depressive disorder: A double-blind, randomized study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 4, 2012, Pages 479-486

  Romera, Irene ^a,b   Pérez, Victor ^c   Menchón, Jose Manuel ^d   Schacht, Alexander ^e   Papen, Rita ^e   Neuhauser, Doris ^f   Abbar, Mocrane ^g   Svanborg, Pär ^f,h   Gilaberte, Inmaculada ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f ELI LILLY AND COMPANY   (United States)

^g DEPARTMENT OF NEUROLOGY   (France)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antidepressant switch; Early switch strategy; Major depressive disorder; Major depressive disorder treatment strategies; Treatment optimization

Indexed keywords

DULOXETINE; ESCITALOPRAM;

ADULT; ANTIDEPRESSANT EARLY SWITCH STRATEGY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HOT FLUSH; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICATION THERAPY MANAGEMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; THIOPHENES;

EID: 84863715548     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825d9958     Document Type: Article

References (43)

1. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003;15(1):17-22. (Pubitemid 36723637)
2. Fava M. Switching treatments for complicated depression. J Clin Psychiatry. 2010;71(2):e04.
3. Hirschfeld RM. The use of mirtazapine in difficult-to-treat patient populations. Hum Psychopharmacol. 2002;17(suppl 1):S33YS36. (Pubitemid 34678889)
4. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64(1):35-39. (Pubitemid 36182227)
5. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry. 2008;63(7):699-704. (Pubitemid 351329277)
6. Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry. 2008;69(1):95-105. (Pubitemid 351282002)
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006b;354(12):1231-1242.
8. Thase ME, Friedman ES, Howland RH. Venlafaxine and treatment-resistant depression. Depress Anxiety. 2000;12(suppl 1):55-62. [Review].
9. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53(9):785-792. (Pubitemid 26303619)
10. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Available at: http://psychiatryonline.org/guidelines.aspx. Accessed June 5, 2012.
11. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 2000;14:3-20. (Pubitemid 30156533)
12. National Institute of Healthy and Clinical Excellence. The Treatment and Management of Depression in Adults, in The British Psychological Society & The Royal College of Psychiatrists, 2010. Available at: http://www.nice.org.uk/ nicemedia/live/12329/45896/45896.pdf. Accessed June 5, 2012.
13. Tadi A, Gorbulev S, Dahmen N, et al. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorderYthe EMC trial. Trials. 2010;11:21.
14. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152(10):1500-1503.
15. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157:1423-1428.
16. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64(4):413-420. (Pubitemid 36547285)
17. Szegedi A, Jansen WT, vanWilligenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353.
18. Lin CH, Lane HY, Chen CC, et al. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31(2):187-193.
19. Nakajima S, Suzuki T, Watanabe K, et al. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):259-264.
20. Nakajima S, Uchida H, Suzuki T, et al. Benefits of switching antidepressants following early nonresponse. Eur Neuropsychopharmacol. 2009;19:S407.
21. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50(5):345-350. (Pubitemid 32816947)
22. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758.
23. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1), 1996. Available at: http://www.ich.org/fileadmin/Public-Web- Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf. Accessed June 5, 2012.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
26. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. (Pubitemid 37289444)
27. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976:217-222, 313-331.
28. Leon AC, Shea MK, Portera L, et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatric Epidemiol. 1992;27(2):78-82.
29. Sheehan DV. The Anxiety Disease. New York, NY: Edited by Charles ScribnerÇ s Sons; 1983.
30. Kind P. The EuroQoL instrument: An index of HRQOL. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996:191-201.
31. Trivedi MH, Rush AJ, Wisniewski SR. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. (Pubitemid 43050100)
32. Wade AG, Schlaepfer TE, Andersen HF, et al. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res. 2009;43(5):568-575.
33. Ciudad A,Á lvarez E, Roca M, et al. Early response and early remission as predictors of good outcome of a depressive episode. J Clin Psychiatry. 2012;73(2):185-191.
34. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry. 1997;54(11):989-991.
35. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289(23):3152-3160. (Pubitemid 37432891)
36. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171- 1180.
37. Romera I, Perez V, Menchón JM, et al. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. Eur Psychiatry. 2010;25(1):58-65.
38. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841-1853.
39. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63(4):424-434.
40. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241. (Pubitemid 32183606)
41. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007;27(6):672-676. (Pubitemid 351339455)
42. Bech P, Tanghøj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol. 2004;7(3):283-290. (Pubitemid 39166462)
43. Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalized anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269-275.